Since its foundation in 2016,
WellmarkerBio("WMBIO") has been developing 9 predictive-biomarker
driven first-in-class anticancer pipelines.
With predictive biomarkers, development
programs with trials employing patient preselection biomarkers are said to have
three-fold higher LOA by the FDA and could reduce the cost and the risk of
administrating ineffective drugs to the patients.
Over the past 5 years, WMBIO made
outstanding operation progress, marked by the advancement of WM-S1-030 in the
phase 1a clinical study and progression of WM-A1 preclinical program. The
company has raised a total of $55 million closing series C round in August 2021
and completed 3 KDDF government projects successfully. Accredited by the
Ministry of Science and ICT of Korea(MIST) as an ‘Excellent Corporation R&D
Center’ and acquiring Inno-Biz certification by the Ministry of SMEs and
Startups(a certification conferred to SMEs equipped with competitive edge based
on the company’s innovate technology), WMBIO is rapidly advancing its robust
pipeline of early stage assets.
“2022 is going to be a vital year for
WellmarkerBio to set in motion an ambitious-yet-achievable plan of developing a
blockbuster drug” said, Dong-Hoon Jin, CEO of Wellmarker Bio. “We are planning
to submit the application for preliminary review in mid-2022. After the IPO,
our priority is to execute on our strategy aimed at out-licensing 2-3 candidate
pipelines to global top pharmaceuticals and develop a portfolio of
clinical-stage products that could address significant unmet medical need in
oncology” he added.
M&A is also on the list of WMBIO’s
business plan. To reinforce core technology and strengthen manpower, Wellmarker
is considering to geographically expand, advance new discoveries through
collaborations with leading companies and institutions worldwide.
“We believe we are well-positioned to
realize our mission of becoming a global pharmaceutical company and advance
precision medicines by positively impacting many patients through our